Prime Intellect Raises $130M Series A for Open Enterprise AI Agent Infrastructure
Prime Intellect raised $130M Series A at $1B valuation. The open superintelligence stack lets enterprises train their own AI agents. Ramp built a model that beat Opus.
Posts by Nexi.fund Labs
AI-Designed AAV Capsids Are Solving Gene Therapy's Delivery Problem
Dyno Therapeutics has become the first company to license AI-designed AAV capsids for both CNS and muscle gene therapies. The Astellas deal, with a $15 million upfront fee, validates that AI-designed biological sequences can pass Big Pharma's diligence process.
Defense Procurement Reform Is Reshaping the Robotics Market — $54.6B in Context
The DoD DAWG $54.6B budget signals a procurement model shift from 10-year cycles to attritable mass. Defense contracts are de-risking commercial robotics investment — $33B+ in VC, 200K drone target by 2027.
AI-Designed Antimicrobial Peptides: The Convergence of Biotech and Field Medicine
Generative AI has discovered nearly a million antimicrobial peptide candidates in two years. The bottleneck has shifted from discovery to delivery and MIT programmable antibacterials point to a path forward.
Defence Tech as an Institutional Asset Class: AVP and Earlybird Launch the €500M E2D Fund
85% of all NATO defence-tech venture funding since 2019 went to the United States. European defence budgets are at their highest since the Cold War. France at €76 billion, Germany at €152 billion, the EU mobilising €800 billion through ReArm Europe. The gap between what governments spend and what
DARPA Robot Medics: Autonomous Battlefield Surgery and Swarm Extraction Reach Phase 1
DARPA funds two parallel programs for autonomous battlefield medicine: MASH (internal bleeding robotics) and Medical Swarm SBIR (extraction + smart tourniquets). NATO's iMEDCAP demonstrated autonomous casualty evacuation at Vigorous Warrior 2026. Phase 1 awards expected Q4 2026–Q1 2027.
AI-Designed De Novo Proteins — Galux Engineering Therapeutic Antibodies from Scratch
Galux raised $29M Series B for AI-driven de novo antibody design. The platform achieved 31.5% hit rate from 50 designs with cryo-EM validated atomic precision.
When AI Learns to Write the Code of Life
First-time AI design of genetic circuits in human cells marks a new phase in synthetic biology and opens a path to truly programmable cell therapies.